NeuroDerm to Announce Updated Topline Results of Phase II Study of ND0612L at the 67th Annual Meeting of the American Academy of Neurology
NeuroDerm announced that its CEO will present at the Cowen and Company 35th Annual Health Care Conference and the 27th Annual ROTH Conference.
NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
NeuroDerm Ltd. today announced the pricing of its initial public offering of 4,500,000 ordinary shares. NeuroDerm shares are expected to begin trading on the Nasdaq Global Market on November 14, 2014 under the ticker symbol “NDRM.”
NeuroDerm Ltd. today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
Company also reports encouraging partial results from Phase IIa study of continuous, subcutaneously delivered high-dose liquid levodopa/carbidopa (ND0612H) therapy for advanced patients
Data presented at the Michael J. Fox Foundation 2014 Parkinson’s Disease Therapeutics Conference
NeuroDerm Announces Presentation of ND0612L Top-line Phase II Results and ND0612H Preliminary Interim Phase IIa Results at the 2014 Parkinson’s Disease Therapeutics Conference
NeuroDerm Ltd. Files Registration Statement for Proposed Initial Public Offering
NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson’s Disease
NeuroDerm Secures $16 Million Financing Round
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.
NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) …
NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease
NeuroDerm, Ltd. announced today that Oded Lieberman, PhD MBA, the company’s Chief Executive Officer, will present at the Jefferies 2013 Global Healthcare Conference in New York on Monday,
“This first trial of ND0612 in man is a significant step in the development of a new levodopa treatment standard for Parkinson’s disease” said Oded S. Lieberman, PhD, NeuroDerm’s Chairman and CEO.
euroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of parkinson’s disease.
NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611…